US fast-food chains adjust menus to accommodate GLP-1 weight-loss drug users

Fast-food chains are modifying menu offerings to include higher protein and lower calorie options in response to the projected adoption of GLP-1 treatments by 12% of US adults by 2026. This shift represents a structural change in consumer demand patterns driven by pharmaceutical intervention rather than traditional dietary trends.